Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial

Background: Imeglimin is a novel type 2 diabetes (T2D) drug that is expected to improve mitochondrial function. In its phase 3 clinical trials in Japanese patients with T2D, the hemoglobin A1c (HbA1c) decrease following imeglimin administration was slow, reaching a plateau after 20–24 weeks of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Osonoi, Takeshi, Shirabe, Shinichiro, Saito, Miyoko, Hosoya, Mitsuru, Douguchi, Satako, Ofuchi, Kensuke, Katoh, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282941/
https://www.ncbi.nlm.nih.gov/pubmed/37351507
http://dx.doi.org/10.3389/fphar.2023.1205021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282941/
https://www.ncbi.nlm.nih.gov/pubmed/37351507
http://dx.doi.org/10.3389/fphar.2023.1205021

Ejemplares similares